Brought to you by 
BMS and Medarex sign an anticancer deal
05 Oct 2021
Executive Summary
In a multi-year agreement, Medarex and Bristol-Myers Squibb will co-develop Medarex's fully human antibody MDX-010 to treat various types of cancer and other diseases. The deal also covers Medarex's MDX-1379, a melanoma peptide vaccine in Phase III development as an adjunct therapy to MDX-010.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Concluded
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BMS and Medarex sign an anticancer deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice